SNWV SANUWAVE HEALTH INC

Sanuwave Announces Strategic Debt Refinancing with New Credit Facility

Sanuwave Announces Strategic Debt Refinancing with New Credit Facility

Credit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by accounts receivable

Both the term loan and revolver have an interest rate of SOFR +350bp

The Company drew approximately $1 million from the revolver at commencement, resulting in total outstanding debt under the new facility of approximately $24 million.

Company announces the repayment in full of NH Expansion debt facility with new credit facility from J.P. Morgan and cash on hand

EDEN PRAIRIE, Minn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced the successful refinancing of its $27.5 million debt facility with NH Expansion Credit Fund Holdings LP (“NH Expansion”) with a new secured credit facility from J.P. Morgan consisting of a $23.0 million term loan, which amortizes over four years and a two-year $5.0 million receivables backed revolving credit facility from which the Company drew approximately $1.0 million at closing. Both facilities have an interest rate of SOFR (Secured Overnight Financing Rate) +350bp and neither facility has any prepayment penalties.

The use of proceeds for the $24 million borrowing at closing was the partial repayment of the NH Expansion debt facility. The remaining $3.5 million owed on the NH Expansion debt facility and additional transaction and initiation costs (including costs to close out the NH Expansion debt facility) of approximately $1.3 million were repaid using cash accumulated from the Company’s operations and from its sale of certain intravascular shockwave patents disclosed in the Company’s Current Report on 8-K filed on August 21, 2025.

“This refinancing marks a pivotal step in strengthening Sanuwave’s financial position,” said Sanuwave CEO Morgan Frank. “The significant reduction in our interest rate, the reduction of our overall debt load, and a move to a set of ‘no prepayment penalty’ terms all position us to better generate cash flow in support of our ongoing mission to pay down our debt out of operating cash flow. We could not ask for a better lender than J.P. Morgan, whose reputation for global leadership in banking needs no introduction. They have already been a great help, and we look forward to working with them going forward.”

Additional details regarding the terms of the new secured credit facility will be included in a Current Report on Form 8-K that the Company intends to file with the Securities and Exchange Commission within four business days.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to our new secured credit facility, our commercial banking facilities, future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.

Contact:



EN
26/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SANUWAVE HEALTH INC

 PRESS RELEASE

Sanuwave Announces Strategic Debt Refinancing with New Credit Facility

Sanuwave Announces Strategic Debt Refinancing with New Credit Facility Credit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by accounts receivable Both the term loan and revolver have an interest rate of SOFR +350bp The Company drew approximately $1 million from the revolver at commencement, resulting in total outstanding debt under the new facility of approximately $24 million. Company announces the repayment in full of NH Expansion debt facility with new credit facility from J.P. Morgan and c...

 PRESS RELEASE

Sanuwave Announces Q2 FY2025 Financial Results

Sanuwave Announces Q2 FY2025 Financial Results Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 versus $2.0 million in Q2 2024. Q2 2025 included equity compensation costs of $1.1 million versus $0 in Q2 2024. Company provides guidance for revenues of $12-$12.7 million for Q3 2025. EDEN PRAIRIE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”...

 PRESS RELEASE

Sanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET)...

Sanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial Results EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 8, 2025, at 8:30 AM (ET) to present its Q2 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information  Toll Free: 1-800-245-3047 Toll/International: 1-203-518-...

 PRESS RELEASE

Sanuwave Health to Present at Canaccord Genuity Growth Conference

Sanuwave Health to Present at Canaccord Genuity Growth Conference EDEN PRAIRIE, Minn., July 22, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, FDA-approved wound care products , today announced, that Morgan Frank, Chief Executive Officer, will present at the 45th Annual Canaccord Genuity Growth Conference, being held August 12–13, 2025, at the InterContinental Hotel in Boston, Massachusetts. Sanuwave’s group presentation is scheduled for Wednesday, August 13, from 9:30 to 9:55 a.m. ET. In addition to the presentation, Mr. Frank will ...

 PRESS RELEASE

Sanuwave Health Announces Preliminary Revenue Results for the Second Q...

Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025) Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 revenue increased between 41% and 42% compared to Q2 2024. First half of 2025 revenue increased 50-51% vs first half of 2024. EDEN PRAIRIE, Minn., July 14, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of ne...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch